The Effect of Lenalidomide on Health‐Related Quality of Life in Patients With Lower‐Risk Non‐del(5q) Myelodysplastic Syndromes: Results From the MDS‐005 Study

[1]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Greenberg,et al.  Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis , 2016, British journal of haematology.

[3]  A. Stamatoullas,et al.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.

[4]  A. Stamatoullas,et al.  Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.

[5]  M. Sprangers,et al.  Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. , 2015, The Lancet. Oncology.

[6]  V. Santini.  Anemia as the Main Manifestation of Myelodysplastic Syndromes. , 2015, Seminars in hematology.

[7]  R. Latagliata,et al.  Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence , 2015, Cancer medicine.

[8]  C. Cogle,et al.  Incidence and Burden of the Myelodysplastic Syndromes , 2015, Current Hematologic Malignancy Reports.

[9]  F. Mandelli,et al.  Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes , 2015, British journal of haematology.

[10]  G. Abel,et al.  Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. , 2014, Blood.

[11]  C. Cleeland,et al.  Symptom Burden In Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) , 2013 .

[12]  C. Finelli,et al.  Costs and quality of life in patients with myelodysplastic syndromes. , 2013, American journal of blood research.

[13]  Wei Li,et al.  Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion , 2013, Experimental and therapeutic medicine.

[14]  V. Santini,et al.  Cost of red blood cell transfusion: an activity-based cost description , 2013 .

[15]  P. Fenaux,et al.  How we treat lower-risk myelodysplastic syndromes. , 2013, Blood.

[16]  A. Stamatoullas,et al.  P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study , 2013 .

[17]  D. Revicki,et al.  Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. , 2013, Leukemia research.

[18]  R. Latagliata,et al.  Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy , 2013, Leukemia & lymphoma.

[19]  G. Abel,et al.  Development of a disease-specific measure of quality of life in myelodysplastic syndromes (MDS): The “QUALMS-1”. , 2012 .

[20]  A. Levis,et al.  Quality of life and physicians' perception in myelodysplastic syndromes. , 2012, American journal of blood research.

[21]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[22]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[23]  J. Astermark,et al.  Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions , 2011, European journal of haematology.

[24]  C. Bloomfield,et al.  NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  M. Laouri,et al.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Latagliata,et al.  Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life , 2010, Leukemia & lymphoma.

[27]  S. Brunskill,et al.  Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review , 2009, American journal of hematology.

[28]  Pierre Fenaux,et al.  Valuation of transfusion-free living in MDS: results of health utility interviews with patients , 2009, Health and quality of life outcomes.

[29]  F. Efficace,et al.  Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes , 2009, Expert review of hematology.

[30]  J. Maciejewski,et al.  Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Sloan,et al.  Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. , 2008, Leukemia research.

[32]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[33]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[34]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Dimitrov,et al.  Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. , 2005, Leukemia research.

[36]  M. Gobbi,et al.  Quality of life and brain function following high‐dose recombinant human erythropoietin in low‐risk myelodysplastic syndromes: a preliminary report , 2004, European journal of haematology.

[37]  A. Levey,et al.  Bias in assessment of health-related quality of life in a hemodialysis population: a comparison of self-administered and interviewer-administered surveys in the HEMO study. , 2003, Journal of the American Society of Nephrology : JASN.

[38]  M. Essink‐bot,et al.  Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes , 2003, British journal of haematology.

[39]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.